Thursday, November 13, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

James Hardie Shares Face Steep Decline Amid Market Challenges

Felix Baarz by Felix Baarz
November 13, 2025
in Analysis, Industrial, Mergers & Acquisitions
0
James Hardie Industries Stock
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

James Hardie Industries is navigating one of its most volatile periods, with its stock value experiencing a dramatic fall. Despite a minor uptick of 0.89% in recent trading, pushing the share price to $26.04, the broader picture reveals a stark year-over-year decline exceeding 51%.

Acquisition Sparks Immediate Sell-Off

The initial downturn occurred in March 2025, triggered by the company’s announcement to acquire The AZEK Company Inc. in a deal valued at approximately $8.75 billion. While intended to expand the product portfolio, this strategic move sent shockwaves through the market, resulting in an immediate 15% drop in the share price. Investor skepticism centered on the financing of the acquisition and the potential integration hurdles within the competitive building materials sector.

Quarterly Earnings Deliver Another Blow

The situation worsened significantly with the release of the Q1 FY26 results in August 2025. The financial report painted a grim picture, revealing a 9% drop in net sales, a 41% decrease in operating income, and a 21% fall in adjusted EBITDA. A particularly weak performance was noted in the North American fiber cement segment, which saw revenues plunge by 12%. The market’s reaction was swift and severe, erasing 30-34% of the stock’s value over two days, sending the price down from $28.43 to $18.64.

Legal and Index-Related Pressures Intensify

The company’s troubles were compounded by legal action from shareholders. Lawsuits allege that James Hardie withheld material information during the period from May 20 to August 18, 2025. Investors have until December 23, 2025, to register as lead plaintiffs in the case.

Should investors sell immediately? Or is it worth buying James Hardie Industries?

From late October to early November, the stock plummeted an additional 23.9%. This steep decline prompted an inquiry from the Australian Securities Exchange (ASX) on November 6, questioning whether undisclosed information was influencing the market. A further 13% loss was recorded on November 8, following the news of the stock’s impending removal from the MSCI Australia Index, effective November 24.

All Eyes on the Next Quarterly Report

The upcoming Q2 FY26 results, scheduled for release this Tuesday, are now seen as a critical juncture for the company. Market analysts are forecasting earnings per share of $0.26 on revenue of $1.2957 billion. The central question remains whether James Hardie can finally demonstrate a turnaround or if it faces another significant downturn.

  • Current Share Price: $26.04 (+0.89%)
  • 12-Month Performance: Down over 51%
  • AZEK Acquisition Impact: -15% in March 2025
  • Q1 FY26 Results Impact: -30-34% in August 2025
  • Next Key Date: Q2 FY26 results on November 18

Despite the substantial losses, some analysts see potential for recovery. Macquarie maintains an “Outperform” rating with a price target of $37.20, while Citi upgraded the stock to “Buy” with a target of A$36.50. The consensus price target of $27.91 suggests possible upside, yet the market’s recent performance tells a more cautious story.

Ad

James Hardie Industries Stock: Buy or Sell?! New James Hardie Industries Analysis from November 13 delivers the answer:

The latest James Hardie Industries figures speak for themselves: Urgent action needed for James Hardie Industries investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 13.

James Hardie Industries: Buy or sell? Read more here...

Tags: James Hardie Industries
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Intellia Therapeutics Stock
Analysis

Clinical Trial Halt Sends Intellia Therapeutics Shares Plunging

November 13, 2025
CytomX Therapeutics Stock
Analysis

CytomX Therapeutics: Navigating Financial Headwinds and Clinical Promise

November 13, 2025
Strategy Stock
Analysis

MicroStrategy’s Valuation Dilemma: When Bitcoin Holdings Eclipse Market Cap

November 13, 2025
Next Post
Twilio Stock

Twilio Shares Surge as AI Momentum Accelerates

Zion Oil, Gas Stock

Zion Oil & Gas Faces Existential Threat After Quarterly Loss

Meta Stock

Meta's Dual Challenge: Navigating Regulatory Hurdles While Betting Big on AI

Recommended

Sabre Stock

Sabre’s Battle for Relevance in a Shifting Travel Technology Landscape

2 months ago
Fiserv Stock

Fiserv Faces Class Action Lawsuit Over Business Practices

3 months ago
Alibaba Stock

Alibaba’s Meteoric Rally Sparks Valuation Concerns Among Analysts

1 month ago
Procter & Gamble Stock

Procter & Gamble Shares: A Market Conundrum Amid Strong Fundamentals

6 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

MicroStrategy’s Valuation Dilemma: When Bitcoin Holdings Eclipse Market Cap

Rigetti Computing: The Financial Reality Behind Quantum Ambition

Kennametal Shares Surge on Stunning Quarterly Performance

PowerFleet Shares Surge on Artificial Intelligence Momentum

H World Group Shares Poised for Strong Quarterly Results

Blackrock TCP Capital: Navigating Turbulent Waters as Investor Confidence Wanes

Trending

Intellia Therapeutics Stock
Analysis

Clinical Trial Halt Sends Intellia Therapeutics Shares Plunging

by Felix Baarz
November 13, 2025
0

A patient death during a critical Phase 3 study has triggered a severe downturn for gene-editing company...

B&G Foods Stock

B&G Foods Stock: Profitability Defies Revenue Challenges

November 13, 2025
CytomX Therapeutics Stock

CytomX Therapeutics: Navigating Financial Headwinds and Clinical Promise

November 13, 2025
Strategy Stock

MicroStrategy’s Valuation Dilemma: When Bitcoin Holdings Eclipse Market Cap

November 13, 2025
Rigetti Stock

Rigetti Computing: The Financial Reality Behind Quantum Ambition

November 13, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Clinical Trial Halt Sends Intellia Therapeutics Shares Plunging
  • B&G Foods Stock: Profitability Defies Revenue Challenges
  • CytomX Therapeutics: Navigating Financial Headwinds and Clinical Promise

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com